Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.

Miller MM, Banville J, Friends TJ, Gagnon M, Hangeland JJ, Lavallée JF, Martel A, O'Grady H, Rémillard R, Ruediger E, Tremblay F, Posy SL, Allegretto NJ, Guarino VR, Harden DG, Harper TW, Hartl K, Josephs J, Malmstrom S, Watson C, Yang Y, Zhang G, Wong P, Yang J, Bouvier M, Seiffert DA, Wexler RR, Lawrence RM, Priestley ES, Marinier A.

J Med Chem. 2019 Aug 22;62(16):7400-7416. doi: 10.1021/acs.jmedchem.9b00186. Epub 2019 Aug 5.

PMID:
31246024
2.

Correction to "Atropisomer Control in Macrocyclic Factor VIIa Inhibitors".

Glunz PW, Mueller L, Cheney DL, Ladziata V, Zou Y, Wurtz NR, Wei A, Wong PC, Wexler RR, Priestley ES.

J Med Chem. 2018 Apr 26;61(8):3752. doi: 10.1021/acs.jmedchem.8b00465. Epub 2018 Apr 5. No abstract available.

PMID:
29620363
3.

Neutral macrocyclic factor VIIa inhibitors.

Wurtz NR, Parkhurst BL, DeLucca I, Glunz PW, Jiang W, Zhang X, Cheney DL, Bozarth JM, Rendina AR, Wei A, Harper T, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.

Bioorg Med Chem Lett. 2017 Jun 15;27(12):2650-2654. doi: 10.1016/j.bmcl.2017.04.008. Epub 2017 Apr 19.

PMID:
28460818
4.

Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors.

Richter JM, Cheney DL, Bates JA, Wei A, Luettgen JM, Rendina AR, Harper TM, Narayanan R, Wong PC, Seiffert D, Wexler RR, Priestley ES.

ACS Med Chem Lett. 2016 Nov 1;8(1):67-72. doi: 10.1021/acsmedchemlett.6b00375. eCollection 2017 Jan 12.

5.

Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.

Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, Callejo M, Miller MM, Lawrence RM, Banville J, Guy J, Maxwell BD, Priestley ES, Marinier A, Wexler RR, Bouvier M, Gordon DA, Schumacher WA, Yang J.

Sci Transl Med. 2017 Jan 4;9(371). pii: eaaf5294. doi: 10.1126/scitranslmed.aaf5294.

PMID:
28053157
6.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.

Wurtz NR, Parkhurst BL, Jiang W, DeLucca I, Zhang X, Ladziata V, Cheney DL, Bozarth JR, Rendina AR, Wei A, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES.

ACS Med Chem Lett. 2016 Sep 17;7(12):1077-1081. eCollection 2016 Dec 8.

7.

Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.

Ladziata VU, Glunz PW, Zou Y, Zhang X, Jiang W, Jacutin-Porte S, Cheney DL, Wei A, Luettgen JM, Harper TM, Wong PC, Seiffert D, Wexler RR, Priestley ES.

Bioorg Med Chem Lett. 2016 Oct 15;26(20):5051-5057. doi: 10.1016/j.bmcl.2016.08.088. Epub 2016 Aug 28.

PMID:
27612545
8.

Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.

Zhang X, Glunz PW, Johnson JA, Jiang W, Jacutin-Porte S, Ladziata V, Zou Y, Phillips MS, Wurtz NR, Parkhurst B, Rendina AR, Harper TM, Cheney DL, Luettgen JM, Wong PC, Seiffert D, Wexler RR, Priestley ES.

J Med Chem. 2016 Aug 11;59(15):7125-37. doi: 10.1021/acs.jmedchem.6b00469. Epub 2016 Aug 2.

PMID:
27455395
9.

Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.

Glunz PW, Mueller L, Cheney DL, Ladziata V, Zou Y, Wurtz NR, Wei A, Wong PC, Wexler RR, Priestley ES.

J Med Chem. 2016 Apr 28;59(8):4007-18. doi: 10.1021/acs.jmedchem.6b00244. Epub 2016 Apr 8. Erratum in: J Med Chem. 2018 Apr 26;61(8):3752.

PMID:
27015008
10.

Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.

Priestley ES, Cheney DL, DeLucca I, Wei A, Luettgen JM, Rendina AR, Wong PC, Wexler RR.

J Med Chem. 2015 Aug 13;58(15):6225-36. doi: 10.1021/acs.jmedchem.5b00788. Epub 2015 Jul 28.

PMID:
26151189
11.

Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors.

Glunz PW, Cheng X, Cheney DL, Weigelt CA, Wei A, Luettgen JM, Wong PC, Wexler RR, Priestley ES.

Bioorg Med Chem Lett. 2015;25(10):2169-73. doi: 10.1016/j.bmcl.2015.03.062. Epub 2015 Mar 30.

PMID:
25881820
12.

Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening.

Cheney DL, Bozarth JM, Metzler WJ, Morin PE, Mueller L, Newitt JA, Nirschl AH, Rendina AR, Tamura JK, Wei A, Wen X, Wurtz NR, Seiffert DA, Wexler RR, Priestley ES.

J Med Chem. 2015 Mar 26;58(6):2799-808. doi: 10.1021/jm501982k. Epub 2015 Mar 12.

PMID:
25764119
13.

Design and Synthesis of Phenylpyrrolidine Phenylglycinamides As Highly Potent and Selective TF-FVIIa Inhibitors.

Zhang X, Jiang W, Jacutin-Porte S, Glunz PW, Zou Y, Cheng X, Nirschl AH, Wurtz NR, Luettgen JM, Rendina AR, Luo G, Harper TM, Wei A, Anumula R, Cheney DL, Knabb RM, Wong PC, Wexler RR, Priestley ES.

ACS Med Chem Lett. 2013 Dec 26;5(2):188-92. doi: 10.1021/ml400453z. eCollection 2014 Feb 13.

14.

Tissue factor-fVIIa inhibition: update on an unfinished quest for a novel oral antithrombotic.

Priestley ES.

Drug Discov Today. 2014 Sep;19(9):1440-4. doi: 10.1016/j.drudis.2014.05.023. Epub 2014 May 29. Review.

PMID:
24881783
15.

Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors.

Glunz PW, Zhang X, Zou Y, Delucca I, Nirschl AH, Cheng X, Weigelt CA, Cheney DL, Wei A, Anumula R, Luettgen JM, Rendina AR, Harpel M, Luo G, Knabb R, Wong PC, Wexler RR, Priestley ES.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5244-8. doi: 10.1016/j.bmcl.2013.06.027. Epub 2013 Jun 21.

PMID:
23845220
16.

Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor.

Priestley ES, De Lucca I, Zhou J, Zhou J, Saiah E, Stanton R, Robinson L, Luettgen JM, Wei A, Wen X, Knabb RM, Wong PC, Wexler RR.

Bioorg Med Chem Lett. 2013 Apr 15;23(8):2432-5. doi: 10.1016/j.bmcl.2013.02.013. Epub 2013 Feb 14.

PMID:
23478148
17.

The synthesis and evaluation of a novel class of (E)-3-(1-cyclohexyl-1H-pyrazol-3-yl)-2-methylacrylic acid hepatitis C virus polymerase NS5B inhibitors.

Martin SW, Glunz P, Beno BR, Bergstrom C, Romine JL, Priestley ES, Newman M, Gao M, Roberts S, Rigat K, Fridell R, Qiu D, Knobloh G, Wang YK.

Bioorg Med Chem Lett. 2011 May 15;21(10):2869-72. doi: 10.1016/j.bmcl.2011.03.086. Epub 2011 Mar 30.

PMID:
21507645
18.

BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies.

Wong PC, Luettgen JM, Rendina AR, Kettner CA, Xin B, Knabb RM, Wexler R, Priestley ES.

Thromb Haemost. 2010 Aug;104(2):261-9. doi: 10.1160/TH10-01-0025. Epub 2010 Jun 29.

PMID:
20589312
19.

Selection of a thiazole urea-resistant variant of bovine viral diarrhoea virus that maps to the RNA-dependent RNA polymerase.

King RW, Scarnati HT, Priestley ES, De Lucca I, Bansal A, Williams JK.

Antivir Chem Chemother. 2002 Sep;13(5):315-23.

PMID:
12630680
20.

P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease.

Priestley ES, De Lucca I, Ghavimi B, Erickson-Viitanen S, Decicco CP.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3199-202.

PMID:
12372533
21.
22.

Specificity of aminoglycoside antibiotics for the A-site of the decoding region of ribosomal RNA.

Wong CH, Hendrix M, Priestley ES, Greenberg WA.

Chem Biol. 1998 Jul;5(7):397-406.

23.

Direct observation of aminoglycoside-RNA interactions by surface plasmon resonance.

Hendrix M, Priestley ES, Joyce GF, Wong CH.

J Am Chem Soc. 1997 Apr 23;119(16):3641-8.

PMID:
11540136

Supplemental Content

Loading ...
Support Center